Traction alopecia and CCCA: what a hairstyle can and can't cause
One of these is straightforwardly caused by pulling on hair, and reverses if you catch it early. The other was blamed on hairstyling for decades before a 2019 genetics paper complicated that story. They get treated as the same condition far more often than the evidence supports.
Disclosure
Nothing here is sponsored and we earn nothing from anything mentioned. If that ever changes, this box will say so before you read a word of the article.
Evidence at a glance
- Traction alopecia is reversible if caught early
- B Well supported: hair loss from mechanical pulling regrows if the tension stops before the follicle scars. Once it doesn't, it's permanent.
- Tight braids, weaves, ponytails and buns are the main drivers
- B Consistent with the clinical literature on where and how this pattern of hair loss shows up.
- CCCA is caused by hairstyling practices
- D Overstated. A 2019 genetics paper found an identifiable gene variant in about a quarter of patients tested, including some who never used relaxers, hot combs or tight styles. A single-cause story doesn't hold up either way — not the old hairstyling-only one, and not a genetics-only replacement for it.
- There's a well-evidenced topical treatment for CCCA
- C Thin. A 2024 panel of 27 hair-loss specialists reached strong agreement on only 20 of 70 proposed treatment statements. This is expert consensus filling a real evidence gap, not a settled trial-backed answer.
- Early diagnosis changes the outcome for CCCA
- B The one point every source agrees on without hedging. Damaged follicles don't regrow once scarring sets in, so the timing of diagnosis is doing most of the work.
These two get lumped together constantly, and they're not the same thing. Traction alopecia is a straightforward mechanical injury: hair pulled tight enough, often enough, damages the follicle, and if you stop before it scars, it grows back. Central centrifugal cicatricial alopecia (CCCA) is a scarring alopecia that starts at the crown and spreads outward, and its cause turns out to be more complicated than "hairstyling" alone. Treating them as one condition, or assuming a hairstyle change fixes both, undersells the one and oversimplifies the other.
Traction alopecia: mechanical, common, and reversible on a deadline
Evidence grade: B — Good evidence
The mechanism isn't controversial. Continuous tension from braids, cornrows, weaves, tight ponytails, buns, and tight turbans or hijabs pulls on the follicle until it gives out. What matters most is the deadline built into that mechanism: caught while the follicle is only inflamed, it recovers once the tension stops. Kept up long enough, the follicle scars, and scar tissue doesn't grow hair back. "In its early stages, traction alopecia is reversible; however, if the pulling continues, it can become irreversible" is about as close to a settled clinical fact as this area gets.
One honest complication: a 2023 retrospective study of 216 patients at a single U.S. hospital (72.7% Black, 98.6% women) found people had typically been losing hair for nearly three years before they were seen, and, among those who returned for follow-up, how long they'd had it made no statistically significant difference to whether they improved. That doesn't overturn the early-is-better principle, which rests on more than one study and on the underlying biology, but it's a reminder that a single real-world dataset doesn't always show a clean line, and duration alone isn't destiny once someone is actually being treated. The practical takeaway survives either way: a low-tension style and an earlier dermatologist visit cost nothing and can only help.
CCCA: the condition a tidy story doesn't fully explain
Evidence grade: C — Suggestive, actively being revised
For years, CCCA was attributed to the same hairstyling practices behind traction alopecia: relaxers, hot combs, tight styles. That theory is now considered incomplete, not because hairstyling plays no role, but because CCCA has been documented in women who never used any of those practices. In 2019, a genetics study sequenced patients with CCCA and found a variant in PADI3, a gene involved in building the hair shaft itself, in 14 of 58 patients studied (24%) across a discovery group of 16 and a replication group of 42, most of African ancestry. A 2025 follow-up from the same research group sequenced 75 further patients and found pathogenic variants not just in PADI3 but in two related genes, S100A3 and TCHH, that build the same hair-shaft protein complex. Worth being precise about what that does and doesn't show: an identifiable variant in one of these genes explains a real minority of cases, not most of them, so this isn't "genetics, not hairstyling" replacing one single-cause story with another. It does mean hairstyling alone was never the whole picture either. Mechanical and chemical stress on a follicle that's already genetically more fragile is a plausible combined picture, and a patient who's never chemically relaxed or tightly styled their hair can still develop CCCA.
What actually has evidence behind it
Evidence grade: C — Suggestive, mostly expert consensus rather than trials
Worth saying plainly: there is no large randomised trial establishing a go-to CCCA treatment. What exists instead is a 2024 modified Delphi panel of 27 dermatologists who specialise in hair and scalp disorders, working through 70 draft treatment statements over three rounds. Strong agreement was reached on only 20 of them. That's not a failure of the panel. It's an honest signal that this field is still working from clinical experience more than from controlled data. The treatments with the most support in that process and in current overview literature are anti-inflammatory: topical or intralesional corticosteroids (lower concentrations preferred on darker skin, to limit thinning and lightening at the injection site) and oral tetracyclines like doxycycline, typically continued for months once things stabilise. Topical minoxidil, metformin and tacrolimus show up as adjuncts in smaller studies, not as primary treatments on their own. None of that is on our Ingredient Index with a CCCA-specific grade, because none of it has the kind of independent trial base we'd want before assigning one.
The one thing not worth debating
Every source here agrees on this without hedging: outcomes depend heavily on how early CCCA is caught, because "hairs will not regrow from permanently damaged hair follicles." Central, crown-first thinning that doesn't have an obvious traction pattern, especially with any tenderness, itching, or a smooth rather than stubbly scalp where hair used to be, is worth a dermatologist visit and often a scalp biopsy well before it's advanced, not after home remedies and looser braids have had a few months to not work. That single piece of timing does more for the outcome than any product on this page.
This is general education, not medical advice. Nothing here accounts for your history, your medication or your skin, and none of it replaces assessment by a qualified clinician. Where we describe what research found, that is a description of a study — not a promise about you.
References
- Afifi L, Oparaugo NC, Hogeling M. Review of traction alopecia in the pediatric patient: Diagnosis, prevention, and management. Pediatric Dermatology, 2021.PubMed 34467569
- Balazic E, Hawkins K, Choi J, Konisky H, Chen A, Kobets K. Traction alopecia: assessing the presentation, management and outcomes in a diverse urban population. Clinical and Experimental Dermatology, 2023.PubMed 37098178
- Malki L, Sarig O, Romano MT, Méchin MC, Peled A, Pavlovsky M, et al. Variant PADI3 in Central Centrifugal Cicatricial Alopecia. New England Journal of Medicine, 2019.PubMed 30763140
- Gabros S, Sathe NC, Masood S. Central Centrifugal Cicatricial Alopecia. StatPearls (NCBI Bookshelf), 2024.Read the source
- Jackson T, Sow Y, Dinkins J, Aguh C, Omueti Ayoade K, Barbosa V, et al. Treatment for central centrifugal cicatricial alopecia—Delphi consensus recommendations. Journal of the American Academy of Dermatology, 2024.PubMed 38341148DOI 10.1016/j.jaad.2023.12.073
- Keller-Rosenthal C, Sarig O, Giladi A, Malovitski K, Rubinstein M, Haitin Y, Larrondo J, Lenzy Y, Dlova NC, McMichael A, Sprecher E. Pathogenic variants affecting peptidyl arginine deiminase 3 and its major substrates underlie central centrifugal cicatricial alopecia. Journal of Investigative Dermatology, 2026.PubMed 41242654
Related condition hub
Your turn
Did this hold up? Tell us honestly — especially if it didn’t.